Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
GLP1 agonists: prescriber inertia or accessibility issue?
Session:
SESSÃO DE POSTERS 09 - OBESIDADE E HIPERTENSÃO: VELHOS CONHECIDOS, NOVAS FERRAMENTAS
Speaker:
Matilde Ferreira
Congress:
CPC 2025
Topic:
L. Cardiovascular Pharmacology
Theme:
31. Pharmacology and Pharmacotherapy
Subtheme:
31.1 Cardiovascular Pharmacotherapy
Session Type:
Cartazes
FP Number:
---
Authors:
Matilde Ferreira; João Adriano Sousa; Maria Isabel Mendonça; Débora Sá; Gonçalo Abreu; Francisco Sousa; Sónia Freitas; Eva Henriques; Mariana Rodrigues; António Drumond; Ana Célia Sousa; Roberto Palma Dos Reis
Abstract
<p style="text-align:justify"><strong>Introduction:</strong><br /> In patients with diabetes and chronic coronary syndrome, treatment with GLP-1 receptor agonists and/or SGLT2 inhibitors is recommended to reduce cardiovascular (CV) risk, independent of glucose control, and as an addition to the standard of care, according to the latest guidelines. However, prescription patterns and data on local availability appear limited, as there is a general perception that access to GLP-1 receptor agonists (GLP-1a) in local pharmacies is low.<br /> <strong>Method:</strong> A substudy of the cross-sectional database from our center cohort was conducted using diabetic patients with chronic coronary syndrome. This observational study aimed to better understand guideline adherence, prescription patterns, and local drug accessibility. Data was obtained through a telephone survey.<br /> <strong>Results:</strong> A total of 261 patients with type 2 diabetes mellitus and a history of coronary cardiovascular events (e.g. myocardial infarction or unstable angina) were surveyed. Of these, 210 (80.5%) were male, with a mean age of 68.1years (range 44-87). SGLT2 inhibitors were prescribed to 79.3% (n=207) of patients. However, 216 patients (82.5%) had not been prescribed GLP-1a in the past two years. Among the 45 patients (17.2%) who had received at least one prescription, the distribution was as follows: 44.4% for semaglutide, 28.9% for dulaglutide, 11.1% for liraglutide and 15.6% for exenatide. Access to the prescribed medication was reported by 88.9% of these patients at least once, while 1.9% never obtained access. On average, patients visited 2.93 pharmacies (range: 1–12) to obtain their medication. Notably, 73.3% of patients reported interrupting treatment at least once due to limited availability, and an alternative GLP-1a was prescribed in 15.6% of cases to address accessibility issues.<br /> <strong>Conclusion:</strong> The proportion of diabetic patients receiving guideline-recommended therapy remains suboptimal, reflecting a persistent gap between findings from randomized clinical trials and real-world clinical practice. GLP-1a therapies are still infrequently prescribed, and when prescribed, they are often difficult to access in local pharmacies. To our knowledge, this is one of the first observational studies to highlight the complexities surrounding GLP-1a prescription and accessibility in routine practice.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site